The stock price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) has dropped by -8.29 compared to previous close of 5.31. Despite this, the company has seen a fall of -11.45% in its stock price over the last five trading days. globenewswire.com reported 2024-08-19 that MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, anticipated in Q1 2025 BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first participants have been dosed in a Phase 1, single ascending dose / multiple ascending dose (SAD/MAD), healthy volunteer study evaluating MRT-6160, a VAV1-directed MGD being developed for systemic and neurological autoimmune diseases. The Company expects to obtain initial data from the Phase 1 study in Q1 2025.
Is It Worth Investing in Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Right Now?
The stock has a 36-month beta value of 1.42. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GLUE is 44.59M, and at present, short sellers hold a 9.82% of that float. On October 24, 2024, the average trading volume of GLUE was 349.86K shares.
GLUE’s Market Performance
GLUE’s stock has seen a -11.45% decrease for the week, with a -14.41% drop in the past month and a 4.28% gain in the past quarter. The volatility ratio for the week is 6.29%, and the volatility levels for the past 30 days are at 6.93% for Monte Rosa Therapeutics Inc The simple moving average for the past 20 days is -5.93% for GLUE’s stock, with a -8.49% simple moving average for the past 200 days.
Analysts’ Opinion of GLUE
Many brokerage firms have already submitted their reports for GLUE stocks, with Wedbush repeating the rating for GLUE by listing it as a “Outperform.” The predicted price for GLUE in the upcoming period, according to Wedbush is $11 based on the research report published on February 15, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see GLUE reach a price target of $18. The rating they have provided for GLUE stocks is “Overweight” according to the report published on January 03rd, 2023.
UBS gave a rating of “Buy” to GLUE, setting the target price at $22 in the report published on October 13th of the previous year.
GLUE Trading at -13.19% from the 50-Day Moving Average
After a stumble in the market that brought GLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.91% of loss for the given period.
Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 6.29%, as shares sank -11.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.04% upper at present.
During the last 5 trading sessions, GLUE fell by -11.45%, which changed the moving average for the period of 200-days by -22.94% in comparison to the 20-day moving average, which settled at $5.18. In addition, Monte Rosa Therapeutics Inc saw -13.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLUE starting from Versant Venture Capital VI, L., who sale 1,132,566 shares at the price of $6.53 back on Sep 20 ’24. After this action, Versant Venture Capital VI, L. now owns 5,099,336 shares of Monte Rosa Therapeutics Inc, valued at $7,395,203 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Monte Rosa Therapeutics Inc, sale 541,897 shares at $6.00 during a trade that took place back on Sep 11 ’24, which means that Versant Venture Capital VI, L. is holding 6,257,218 shares at $3,251,382 based on the most recent closing price.
Stock Fundamentals for GLUE
Current profitability levels for the company are sitting at:
- -9.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Monte Rosa Therapeutics Inc stands at -8.99. The total capital return value is set at -0.46. Equity return is now at value -59.51, with -41.88 for asset returns.
Based on Monte Rosa Therapeutics Inc (GLUE), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.38. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -149.11.
Currently, EBITDA for the company is -137.09 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of 16.15. The receivables turnover for the company is 1.47for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.56.
Conclusion
To sum up, Monte Rosa Therapeutics Inc (GLUE) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
